- Home
- NUVL vs TREX Comparison
NUVL vs TREX Comparison
Compare NUVL & TREX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- TREX
- Stock Information
- Founded
- NUVL 2017
- TREX 1996
- Country
- NUVL United States
- TREX United States
- Employees
- NUVL N/A
- TREX N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- TREX
- Sector
- NUVL Health Care
- TREX
- Exchange
- NUVL Nasdaq
- TREX Nasdaq
- Market Cap
- NUVL 6.5B
- TREX 5.5B
- IPO Year
- NUVL 2021
- TREX 1999
- Fundamental
- Price
- NUVL $104.59
- TREX $48.30
- Analyst Decision
- NUVL Strong Buy
- TREX Buy
- Analyst Count
- NUVL 11
- TREX 16
- Target Price
- NUVL $121.45
- TREX $71.00
- AVG Volume (30 Days)
- NUVL 498.8K
- TREX 1.6M
- Earning Date
- NUVL 11-10-2025
- TREX 11-04-2025
- Dividend Yield
- NUVL N/A
- TREX N/A
- EPS Growth
- NUVL N/A
- TREX N/A
- EPS
- NUVL N/A
- TREX 1.73
- Revenue
- NUVL N/A
- TREX $1,129,138,000.00
- Revenue This Year
- NUVL N/A
- TREX $8.82
- Revenue Next Year
- NUVL N/A
- TREX $7.42
- P/E Ratio
- NUVL N/A
- TREX $28.07
- Revenue Growth
- NUVL N/A
- TREX N/A
- 52 Week Low
- NUVL $55.54
- TREX $47.98
- 52 Week High
- NUVL $103.69
- TREX $80.74
- Technical
- Relative Strength Index (RSI)
- NUVL 71.49
- TREX 34.57
- Support Level
- NUVL $90.00
- TREX $48.75
- Resistance Level
- NUVL $99.94
- TREX $50.62
- Average True Range (ATR)
- NUVL 4.59
- TREX 1.70
- MACD
- NUVL 1.10
- TREX 0.00
- Stochastic Oscillator
- NUVL 100.00
- TREX 6.75
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About TREX Trex Company Inc.
Trex Co Inc is a manufacturer of wooden alternative decking products. The company offers outdoor products in the decking, railing, porch, fencing, trim, steel deck framing, and outdoor lighting categories. Its products are sold under the Trex brand and manufactured in the United States. Further, the company licenses its Trex brand to third parties to manufacture and sell products under the Trex trademark. The distribution is focused on wholesale distributors and retail lumber dealers, which in turn sell Trex products to homeowners and contractors, with an emphasis on professional contractors, remodelers, and homebuilders. The company operates in one reportable segment i.e. Trex Residential.